Page 109 - 南京医科大学自然版

第44卷第5期 李盈盈，冯黎黎，韩 峰. 胶质母细胞瘤对替莫唑胺耐药机制的研究进展［J］.
2024年5月 南京医科大学学报（自然科学版），2024，44（5）：688-697 ·697 ·

rus［J］. N Engl J Med，2018，379（2）：150-161 （Suppl 6）：S25-S34
［66］LIAU L M，ASHKAN K，BREM S，et al. Association of au⁃ ［74］STUPP R，TAILLIBERT S，KANNER A A，et al. Mainte⁃
tologous tumor lysate ⁃ loaded dendritic cell vaccination nance therapy with tumor ⁃ treating fields plus temozolo⁃
with extension of survival among patients with newly diag⁃ mide vs temozolomide alone for glioblastoma：a random⁃
nosed and recurrent glioblastoma：a phase 3 prospective ized clinical trial［J］. JAMA，2015，314（23）：2535-2543
externally controlled cohort trial［J］. JAMA Oncol，2023， ［75］STUPP R，TAILLIBERT S，KANNER A，et al. Effect of tu⁃

9（1）：112-121 mor ⁃ treating fields plus maintenance temozolomide vs
［67］NARITA Y，ARAKAWA Y，YAMASAKI F，et al. A ran⁃ maintenance temozolomide alone on survival in patients
domized，double⁃blind，phase Ⅲ trial of personalized pep⁃ with glioblastoma：a randomized clinical trial［J］. JAMA，
tide vaccination for recurrent glioblastoma［J］. Neuro On⁃ 2017，318（23）：2306-2316
col，2019，21（3）：348-359 ［76］TOMS S A，KIM C Y，NICHOLAS G，et al. Increased com⁃
［68］PICCIRILLO S G M，REYNOLDS B A，ZANETTI N，et pliance with tumor treating fields therapy is prognostic for
al. Bone morphogenetic proteins inhibit the tumorigenic improved survival in the treatment of glioblastoma：a sub⁃
potential of human brain tumour ⁃ initiating cells［J］. group analysis of the EF⁃14 phase Ⅲ trial［J］. J Neuroon⁃
Nature，2006，444（7120）：761-765 col，2019，141（2）：467-473
［69］BOS E M，BINDA E，VERPLOEGH I S C，et al. Local de⁃ ［77］XU C，YUAN X Y，HOU P Y，et al. Development of glio⁃
livery of hrBMP4 as an anticancer therapy in patients blastoma organoids and their applications in personalized
with recurrent glioblastoma：a first ⁃ in ⁃ human phase 1 therapy［J］. Cancer Biol Med，2023，20（5）：353-368
dose escalation trial［J］. Mol Cancer，2023，22（1）：129 ［78］JACOB F，SALINAS R D，ZHANG D Y，et al. A patient⁃
［70］WANG X X，YANG K L，WU Q L，et al. Targeting pyrimi⁃ derived glioblastoma organoid model and biobank recapit⁃
dine synthesis accentuates molecular therapy response in ulates inter ⁃ and intra ⁃ tumoral heterogeneity［J］. Cell，
glioblastoma stem cells［J］. Sci Transl Med，2019，11 2020，180（1）：188-204
（504）：eaau4972 ［79］ANDREATTA F，BECCACECI G，FORTUNA N，et al.
［71］MUN E J，BABIKER H M，WEINBERG U，et al. Tumor⁃ The organoid era permits the development of new applica⁃
treating fields：a fourth modality in cancer treatment［J］. tions to study glioblastoma［J］. Cancers，2020，12（11）：
Clin Cancer Res，2018，24（2）：266-275 3303
［72］STUPP R，WONG E T，KANNER A A，et al. NovoTTF⁃ ［80］WEN J，LIU F K，CHENG Q，et al. Applications of organ⁃
100A versus physician’s choice chemotherapy in recur⁃ oid technology to brain tumors［J］. CNS Neurosci Ther，
rent glioblastoma：a randomised phase Ⅲ trial of a novel 2023，29（10）：2725-2743
treatment modality［J］. Eur J Cancer，2012，48（14）： ［81］LOONG H H F，WONG A M，CHAN D T M，et al. Patient⁃
2192-2202 derived tumor organoid predicts drugs response in glioblas⁃
［73］KANNER A A，WONG E T，VILLANO J L，et al. Post toma：a step forward in personalized cancer therapy?［J］. J
Hoc analyses of intention⁃to⁃treat population in phase Ⅲ Clin Neurosci，2020，78：400-402
TM
comparison of NovoTTF⁃100A system versus best physi⁃ ［收稿日期］ 2024-01-20
cian’s choice chemotherapy［J］. Semin Oncol，2014，41 （本文编辑：陈汐敏）